I help companies of all sizes and stages of development negotiate complex technology and commercial transactions.
Mark Potash advises life sciences and technology companies on a broad range of corporate matters and transactions involving intellectual property, including licenses, collaborations, mergers & acquisitions and joint ventures. His practice focuses on drafting and negotiating complex collaboration and license agreements, as well as development, supply, distribution, manufacturing, services and other commercial agreements, for both established and emerging companies.
Mark has substantial experience negotiating software license and software-as-a-service agreements. He also advises public and private companies on a range of corporate matters, including corporate formation, financings and general corporate governance matters.
Mark currently serves as a member of the firm’s Hiring Committee.
Boston College Law School, J.D., magna cum laude, Order of the Coif, 2015
Boston College, B.S., summa cum laude, Scholar of the College, 2012
Bar and Court Admissions
BAR ADMISSIONS
Massachusetts
Experience
LIFE SCIENCES
Novo Nordisk A/S (NYSE: NVO) in multiple matters, including:
a collaboration and license agreement with Gensaic, Inc. to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease, with upfront and milestone payments of up to $354 million per target, plus tiered royalties
a collaboration, development and license agreement with Aspect Biosystems to develop up to four bioprinted tissue products for the treatment of diabetes and obesity, with $75 million upfront and up to $650 million in milestones per product, plus tiered royalties
AcuraStem in a license agreement with Takeda (NYSE: TAK) to develop and commercialize PIKFYVE targeted therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS), for an upfront and milestone payments totaling up to $580 million, plus tiered royalties
Alloy Therapeutics in multiple matters, including:
a strategic collaboration and licensing agreement with Takeda to develop and commercialize Takeda’s induced pluripotent stem cell (iPSC) driven CAR-T cell platform (iCAR-T) and CAR-NK platform (iCAR-NK) for cell therapy in oncology indications
in the formation of Broadwing Bio LLC, a joint venture with Maze Therapeutics to develop targeted antibody therapies for the treatment of ophthalmic diseases
its $75 million Series C financing, led by 8VC, Presight Capital and Peter Thiel
Ginkgo Bioworks (Nasdaq: DNA) in various collaboration and license agreements, including:
with Merck (NYSE: MRK) to improve production efficiency and increase yields in biologic manufacturing for up to $490 million in upfront research fees, research milestone fees, option license payments and commercial milestone payments
with Boehringer Ingelheim to collaborate in mining Ginkgo’s metagenomic sequence database for a specified number of projects up to an aggregate total of $406 million
with Octarine Bio, a synthetic biology company developing new sustainable bio-based ingredients, in a multi-stage partnership focused on compounds in the tryptophan pathway
with Merck (NYSE: MRK) worth up to $144M in milestone payments to engineer enzymes for use as biocatalysts in Merck’s active pharmaceutical ingredient (API) manufacturing efforts
with Novo Nordisk (NYSE: NVO) to create novel expression hosts for pharmaceutical products addressing diabetes and other serious chronic diseases
with Microba Life Sciences (ASX: MAP) to identify single-strain, live bacteria product candidates for use against autoimmune diseases
with Agenus (Nasdaq: AGEN) and its subsidiary SaponiQx to develop saponin molecules for high-efficacy and long-lasting protection for pandemic vaccines
with Cambium Biomaterials for the development and commercialization of sustainable biomaterials for use in applications across a range of industries
with Givaudan to accelerate development and enhance Givaudan's portfolio of taste and scent ingredients
with Sumitomo Chemical Co. to significantly increase the production efficiency and sustainability of a key bio-based commercial product
with Biogen (Nasdaq: BIIB) to develop a next-generation recombinant adeno-associated virus (AAV) production platform
Jana Care in a collaboration agreement with Roche Diagnostics to develop and distribute Jana Care’s point-of-care blood testing platform for chronic kidney disease and congestive heart failure
MedRhythms in a license agreement with Biogen (Nasdaq: BIIB) to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis, for $120.5 million in upfront and potential milestone payments, plus royalties
Intellia Therapeutics (Nasdaq: NTLA) in a cross-border collaboration with SparingVision using Intellia’s proprietary CRISPR/Cas9 platform to develop new gene therapies directed to up to three ocular targets for a 10% equity ownership stake in SparingVision, milestone payments of up to approximately $200 million per product, and royalties, as well as an option to US commercialization rights for two of three targets
Ginkgo Bioworks (Nasdaq: DNA) in the launch of Concentric by Ginkgo, the company’s public health and biosecurity initiative, to provide COVID-19 testing solutions to states, cities and school districts
Dicerna Pharmaceuticals (Nasdaq: DRNA) in multiple collaboration and license agreements, including:
a global collaboration agreement with Novo Nordisk A/S to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases
a global collaboration and license agreement in excess of $1.67 billion in upfront and milestone payments, plus royalties, with Roche to develop and commercialize a treatment for chronic Hepatitis B Virus (HBV) infection
a global licensing and research collaboration with Eli Lilly focused on potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain
a collaboration with Alexion Pharmaceuticals to discover and develop RNA interference therapies for complement-mediated diseases
Personalized health network PatientsLikeMe in its investment and partnering agreements with digital life company iCarbonX
TECHNOLOGY
Motional, a global leader in driverless technology, in a landmark agreement with Lyft (Nasdaq: LYFT) to launch a multimarket robotaxi service in major US cities
Position Imaging, a technology company focused on innovations to improve the logistics industry, in a landmark partnership with global technology firm Hitachi-LG Data Storage, Inc.
Rental platform Zumper in multiple financing rounds, including:
its $60 million Series D round led by e.ventures
its $46 million Series C financing led by Axel Springer and Stereo Capital
its $17.6 million Series B funding led by Breyer Capital and Foxhaven Asset Management, including follow-up funding from existing investors
Cybersecurity company GreatHorn in multiple transactions, including:
a $13 million funding round co-led by RRE Ventures and .406 Ventures
its $6.3 million Series A financing led by Techstars Venture Capital Fund and .406 Ventures
Honors & Involvement
HONORS
Best Lawyers: Ones to Watch - Corporate Law (2023-2026), Mergers & Acquisitions Law (2023-2026), Venture Capital Law (2023-2026), and Securities / Capital Markets Law (2026)
Boston College Law Review: Articles Editor
INVOLVEMENT
Boston Bar Association, Member
Massachusetts LGBTQ Bar Association, Member
Other Events
"IP Strategies from Academia to Industry in Life Sciences," Foley Hoag's Colorado Life Sciences Summit (November 2025)
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
